RecruitingNot applicableNCT06704321

Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD

Studying NON RARE IN EUROPE: Non-alcoholic fatty liver disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Valbiotis
Principal Investigator
André Marette, PhD
Laval University
Intervention
TOTUM-448(dietary_supplement)
Enrollment
70 target
Eligibility
18-75 years · All sexes
Timeline
20242025

Study locations (1)

Collaborators

CHU de Quebec-Universite Laval · Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Laval University · Valbiotis Canada inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06704321 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Non-alcoholic fatty liver disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Non-alcoholic fatty liver disease

← Back to all trials